Navigation Links
Study of Pathwork Diagnostics' Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
Date:12/14/2007

SUNNYVALE, Calif., Dec. 14 /PRNewswire/ -- Pathwork Diagnostics, a genomics-based diagnostics company focused on oncology, announced that its Pathwork(R) Tissue of Origin Test is the focus of a study published in the January issue of The Journal of Molecular Diagnostics. Pathwork's genomics-based test is designed to help determine a tumor's origin so that tissue-specific management can begin. The study, performed by principal investigator Federico A. Monzon, M.D., and colleagues from the University of Pittsburgh, Virginia Commonwealth University and Stanford University, examined the analytical performance characteristics and reproducibility of the Tissue of Origin Test.

There are an estimated 200,000 cancer patients with an uncertain primary diagnosis on their cancers each year in the U.S.(1),(2),(3) These people may benefit from additional diagnostic information to determine the tissue of origin for their cancer. One study showed that, in such cases, the primary tumor site is identified only 25 percent of the time using traditional diagnostic tools. National Comprehensive Cancer Network guidelines emphasize the importance of identifying the tissue of origin so that management specific to the primary cancer can begin.

The Pathwork Tissue of Origin Test measures the expression of more than 1600 genes and compares a tumor's gene expression "signature" against those of 15 known tissue types. The test uses microarray technology, which enables large numbers of genes to be evaluated at the same time, using the proven, commercially available Affymetrix microarray platform.

In the study, 60 archived tissue specimens from poorly and undifferentiated tumors (metastatic and primary) were analyzed at four laboratories representing a wide range of pre-analytical conditions. Reproducibility was analyzed by cross-wise comparisons of all 4 sites. Cross-laboratory comparisons, performed using a variety of measures, showed highly reproducible results between laboratories. Overall concordance between laboratories in terms of final tissue of origin calls was 93.8%.

"As a result of the study, we concluded that the Pathwork Tissue of Origin Test is a robust assay that produces consistent results in diverse laboratory conditions reflecting the pre-analytical variations found in the everyday clinical practice of molecular diagnostics laboratories," explained Catherine I. Dumur, Ph.D., of Virginia Commonwealth University, lead author of the manuscript.

"This test has the potential to be an effective aid in the diagnosis of cancer patients presenting with poorly differentiated and undifferentiated tumors," commented Dr. Monzon, now at The Methodist Hospital in Houston, TX.

Note: The Pathwork Tissue of Origin Test is not cleared by the FDA for sale in the U.S. It is for Investigational Use Only.

About Pathwork Diagnostics

Pathwork Diagnostics, based in Sunnyvale, California, develops and delivers genomics-based diagnostics that advance cancer care. The company solves unmet clinical needs in oncology by using innovative technology to harness the power of genomics information and apply it in a robust, reproducible and reliable manner. Pathwork Diagnostics plans to deliver FDA-cleared microarray-based diagnostic tests for oncology to the clinical laboratory. The company's initial tests will consist of Pathwork Diagnostics' proprietary analytics and a companion Pathchip(TM) microarray, which runs on the proven Affymetrix instrument system. The company's first test -- the Pathwork(R) Tissue of Origin Test -- is designed to be an aid in the diagnosis of the tissue of origin in patients with poorly or undifferentiated tumors or metastases.

(1) Pavlidis, Fizazi. Cancer of unknown primary. Critical Reviews in

Oncology Hematology 54 (2005) 243-50.

(2) Tong et al. Incidence, costs of care and survival of Medicare

beneficiaries diagnosed with carcinoma of unknown primary. Abstract

presented at ASCO 2006.

(3) Pathwork Diagnostics analysis.


'/>"/>
SOURCE Pathwork Diagnostics
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... -- ITL Limited, ( ASX: ITD ), an innovative diversified healthcare ... ended 31 December 2016 compared with the previous corresponding period. A ... here . Highlights ... Earnings per share of 2.2 cents (Dec 2015: 1.2 ... $15.7m; up 11%) Profit before tax of $2.12m ...
(Date:2/23/2017)... Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die Guian ... Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden Strategien ... einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... REDWOOD CITY, Calif. , Feb. 23, 2017 ... specialty pharmaceutical company focused on the development and ... moderate-to-severe acute pain, announced that it will release ... close on Thursday, March 2nd, 2017. AcelRx management ... p.m. Eastern Time (1:30 p.m. Pacific Time) on ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... 2017 , ... On February 22, 2017 the U.S. Department ... withdraw previous guidance issued by the Obama Administration requiring schools to treat transgender ... by the Obama Administration came in response to a growing number of states ...
(Date:2/23/2017)... ... 2017 , ... Rare Disease Report®, which is the only ... Disease Day events, hosted by the Rare Disease Legislative Advocates (RDLA) on February ... e-newsletter and quarterly publication, will be conducting interviews with patients and advocates in ...
(Date:2/23/2017)... North Hollywood, CA (PRWEB) , ... February 23, 2017 , ... ... are pleased to announce that they are sponsoring a raffle. Throughout the month of ... drawing. Winners will receive a gift card for a dinner for two at the ...
(Date:2/23/2017)... ... February 23, 2017 , ... On ... a diverse symposium on “Doping in Sport: How the Culture Might Change,” ... & Hampton LLP. The symposium will be held at Pepperdine University in Malibu, ...
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global data ... that Premier Research, a leading clinical development service provider, has selected ERT’s Trial ... complex, due in part to an array of circumstances including the use of ...
Breaking Medicine News(10 mins):